Navigation Links
Therapure Biopharma Inc. Awarded US Government Contract for Development of Anti-Nerve Gas Agent

Mississauga, ON (PRWEB) June 11, 2013

Therapure Biopharma Inc., a contract development and manufacturing organization (CDMO) of biotherapeutics, is pleased to announce the company will participate as a subcontractor for DynPort Vaccine Company LLC (DVC), a CSC company, that was awarded a US cost-plus-fixed-fee contract with a maximum value of $157.3 million (prime contract number W911QY-13-C-0056) by the US Department of Defense (DoD) to support the development of a prophylactic countermeasure to prevent the effects of organophosphorus nerve agent poisoning.

Therapure’s subcontract under the above prime contract includes process optimization as well as manufacture of all clinical and nonclinical materials (drug product) to support DVC’s contract to develop, test and obtain the US Food and Drug Administration (FDA) approval for human plasma-derived butyrylcholinesterase (HuBChE), a blood plasma protein that binds and inactivates nerve agents. Mr. Nick Green, Therapure’s President and Chief Executive Officer, said: “We are delighted to partner with DVC to develop and manufacture medical counter measures for the US Department of Defense as part of a defense strategy against a wide range of nerve gases. Therapure successfully completed a rigorous selection and approval process to serve as the manufacturing subcontractor under the prime contract, which is a testament to the Company’s standards and capabilities in biomanufacturing. It is an honor to be part of this very critical initiative to protect US Servicemen and women.”

Any opinions, findings and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the U.S. Department of Defense, Department of the Army, Chemical Biological Medical Systems Joint Project Management Office (CBMS JPMO), Medical Identification and Treatment Systems Joint Product Management Office (MITS JPMO).

Therapure Biopharma Inc. is an integrated biopharmaceutical company that develops, manufactures, purifies and packages therapeutic proteins. As a CDMO, Therapure Biopharma applies scientific, manufacturing, and downstream purification expertise with an intimate understanding of advanced biology, complex proteins, and regulatory processes to develop innovative and efficient solutions to advance client products from discovery to market. Therapure’s 130,000 sq. ft. facility includes manufacturing, research and quality-control laboratories and is built to U.S. FDA, EMA, MHRA and Health Canada standards.

For more information, please visit:

Company Contact:
Dina Iezzi
Director, Marketing and Special Projects

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Monoclonal Antibodies Market Dealmaking in Biopharma Industry Analyzed in New Research Report at
2. Scientist awarded $1 million grant to develop tools for hepatitis C treatment discovery
3. $9 million grant awarded to UH to study, treat learning disabilities
4. Kessler Foundation scientist awarded $554,000 for multiple sclerosis employment research
5. Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks
6. Grant awarded to help improve problem-solving skills for deaf and hard-of-hearing students
7. Southeast program to fight diabetes awarded nearly $10 million by HHS
8. Clemson professor awarded nearly $600,000 4-year grant to study language of plants
9. 29 Johns Hopkins stem cell researchers awarded funding
10. Einstein awarded $6 million grant to develop new TB vaccine against drug-resistant strains
11. FirstVitals Health and Wellness, Inc. awarded $4 Million CMS Innovation Grant for Unique Telehealth Diabetes Progam Focused on Glycemic Control and Prevention of Diabetic Foot Complications
Post Your Comments:
(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced ... feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as a ... has released tools for healthy coping following a traumatic event. , Trauma sufferers tend ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology: